Health
Nova Bio raises $14 million to scale rapid diagnostic tests
Funding will support manufacturing and regulatory submissions.
BOSTON, 10 Nov 2026
Nova Bio today announced a $14 million Series A round to expand production of its rapid diagnostic tests and support regulatory submissions in three markets. The round was led by existing investors.
“This capital lets us move from pilot batches to steady supply for the clinics that asked for it.”
About: Nova Bio develops low-cost diagnostic tests for clinics and community health programmes.